Company Filing History:
14 out of 2,886 
2 out of 3 
1 out of 1 Years Active: 2018-2025
Title: Sarah Bettigole: Innovator in Cancer Treatment
Introduction
Sarah Bettigole is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of small molecule inhibitors. With a total of 17 patents to her name, Bettigole is recognized for her groundbreaking work in targeting specific protein families involved in cancer progression.
Latest Patents
Among her latest patents, Bettigole has developed IRE1 small molecule inhibitors. These inhibitors target the IRE1 protein family members, providing methods for treating or ameliorating cancer in subjects. The inhibitors can be used for both solid and hematologic cancers. Another notable patent involves heterocyclic inhibitors of ENPP1, which relates to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). This patent details triazolopyrimidine and imidazolopyrimidine inhibitors and their applications in treating diseases mediated by ENPP1.
Career Highlights
Bettigole has worked with esteemed institutions such as Cornell University and Volastra Therapeutics, Inc. Her work has been pivotal in advancing the understanding and treatment of cancer through innovative therapeutic approaches.
Collaborations
Throughout her career, Bettigole has collaborated with notable colleagues, including Joseph P. Vacca and Dansu Li. These collaborations have further enhanced her research and contributed to her success in the field.
Conclusion
Sarah Bettigole stands out as a leading inventor in the realm of cancer treatment, with her innovative patents and collaborations paving the way for future advancements. Her dedication to research continues to impact the medical community positively.